Praxis Precision Medicines, Inc.
PRAX evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $9.34B
- Lead Asset:
- Elsunersen (Phase 3)
What it means
What to watch
Prepared research question
What matters most for PRAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRAX
Praxis Precision Medicines is a fully integrated precision neuroscience biopharmaceutical company developing a multimodal CNS portfolio spanning epilepsy and movement disorders, anchored by four late-stage product candidates including ulixacaltamide and relutrigine, both of which have NDAs accepted for FDA review [sec · filed 2026-04-30] [sec_mda · as of 2026-08-06].
Key risk: Concentration on ulixacaltamide
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 10 clinical trials · 2 catalysts for Praxis Precision Medicines, Inc..
Praxis Precision Medicines is a fully integrated precision neuroscience biopharmaceutical company developing a multimodal CNS portfolio spanning epilepsy and movement disorders, anchored by four late-stage product candidates including ulixacaltamide and relutrigine, both of which have NDAs accepted for FDA review [sec · filed 2026-04-30] [sec_mda · as of 2026-08-06].
- Cash & equivalents of $474.8M as of 2026-06-30 [sec].
- Net income of -$83.7M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $1,341.0M as of 2026-06-30 [sec].
- NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A DEE) have been accepted for FDA review [sec_mda · as of 2026-08-06].
- The FDA completed a Bioresearch Monitoring (BIMO) inspection for both ulixacaltamide and relutrigine NDAs with no Form 483 issued [sec_mda · as of 2026-08-06].
What works
- Four late-stage product candidates (ulixacaltamide, relutrigine, vormatrigine, elsunersen) provide a diversified pipeline across movement disorders and epilepsy [sec · filed 2026-04-30].
- Cash runway appears extended: $474.8M cash as of 2026-06-30 supports ongoing clinical programs and pre-commercial preparations [sec].
- Successful completion of a BIMO inspection without a Form 483 for both ulixacaltamide and relutrigine NDAs indicates strong regulatory compliance [sec_mda · as of 2026-08-06].
What to weigh
- The company has accumulated substantial operating losses, with net income of -$83.7M for the period ended 2026-06-30 [sec].
- Expenses are expected to increase as the company scales manufacturing, sales, and marketing infrastructure for potential product launches [sec_mda · as of 2026-08-06].
- Pipeline value is heavily concentrated on the approval of ulixacaltamide for essential tremor, creating binary outcome risk [news · published 2026-07-22].
From the filings
Quoted directly from source documents.
Praxis is a fully integrated precision neuroscience biopharmaceutical company focused on CNS disorders.
“We are a fully integrated, precision neuroscience biopharmaceutical company focused on central nervous system ("CNS") disorders characterized by neuronal excitation-inhibition imbalance.”
SEC filings · April 30, 2026
Ulixacaltamide and relutrigine NDAs have been accepted for FDA review.
“prepare for the potential commercialization of ulixacaltamide, for which we have submitted an NDA to the FDA that has been accepted for review”
SEC MD&A · August 6, 2026
BIMO inspection completed without a Form 483.
“The inspection was completed successfully, and no form 483 was issued.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-12-27 · PDUFA · relutrigine — FDA decision on the NDA for relutrigine for SCN2A DEE.
- 2027-01-29 · PDUFA — ulixacaltamide — FDA decision on the NDA for ulixacaltamide for essential tremor.
Risks & what to watch (3)›
Key risks
- Concentration on ulixacaltamide — 70% of pipeline value tied to ulixacaltamide approval for essential tremor, creating binary outcome risk [news · published 2026-07-22].
- Sustained operating losses — Net income of -$83.7M as of 2026-06-30; expenses expected to increase with commercialization preparations [sec] [sec_mda · as of 2026-08-06].
- Regulatory binary outcomes — Multiple late-stage programs face binary FDA decisions; any rejection could significantly impact pipeline value [sec · filed 2026-04-30].
What to watch
- PDUFA date for relutrigine on 2026-12-27 [catalyst].
- PDUFA date for ulixacaltamide on 2027-01-29 [catalyst].
- Ongoing ENERGY program for vormatrigine, including POWER1, POWER2, and other studies [sec · filed 2026-04-30].
- EMBRAVE Part A study evaluating elsunersen in early onset SCN2A DEE [sec · filed 2026-04-30].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Praxis Precision Medicines, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Praxis Precision Medicines, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.04 · 0% dilution
Lead: Phase 3
3 candidates
2 upcoming, next in ~74d
0 buys · 12 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 13.6%
- Days to cover
- 9.3
- Shares short
- 3,775,673
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRAX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Praxis Precision Medicines, Inc.?
Praxis Precision Medicines is a fully integrated precision neuroscience biopharmaceutical company developing a multimodal CNS portfolio spanning epilepsy and movement disorders, anchored by four late-stage product candidates including ulixacaltamide and relutrigine, both of which have NDAs accepted for FDA review [sec · filed 2026-04-30] [sec_mda · as of 2026-08-06].
What is Praxis Precision Medicines, Inc.'s lead drug candidate?
Praxis Precision Medicines, Inc.'s most advanced tracked candidate is Elsunersen (Phase 3) for Epileptic Encephalopathy.
What is Praxis Precision Medicines, Inc.'s next catalyst?
Praxis Precision Medicines, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA: relutrigine" — expected December 27, 2026.
Who is the CEO of Praxis Precision Medicines, Inc.?
Mr. Marcio Silva De'Souza M.B.A. is the chief executive officer of Praxis Precision Medicines, Inc. (PRAX).
Where is Praxis Precision Medicines, Inc. headquartered?
Praxis Precision Medicines, Inc. (PRAX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.